drugset / Trial / NCT00050661
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.
Timeline
- Start
- 1997-10
- Primary completion
- 2004-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclizumab | Monoclonal antibody | 1 mg/kg | Intravenous |